FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Quality, Data Issues at Mylan Facility in India

FDA warns a Viatris Mylan drug manufacturing facility in Pradesh, India, about CGMP violations involving quality and data issues.

latest-news-card-1
Human Drugs

Boxed Warning for Veozah Liver Injury

FDA adds a liver injury Boxed Warning to labeling for Astellas menopause hot flash drug Veozah.

latest-news-card-1
Human Drugs

Lexicon Dropping Zynquista After CRL

Lexicon stops development of its diabetes drug Zynquista that received an FDA complete response letter.

latest-news-card-1
Medical Devices

Hologic BioZorb Marker Recall Class 1: FDA

FDA says a Hologic 3/2024 recall correction of BioZorb Markers was Class 1.

latest-news-card-1
Human Drugs

UCB Minzasolmin Parkinsons Study Misses Endpoints

UCB says it is ending the development of minzasolmin, a drug it was working on with Novartis to treat early Parkinsons disease, after the drug missed ...

latest-news-card-1
Medical Devices

FDA Alert on Baxter Solution Sets

FDA issues an alert against the use of certain Baxter Solution Sets with Duo-Vent Spikes because they were incorrectly assembled with inverted slide c...

latest-news-card-1
FDA General

Temple Retires; Bumpus Leaves FDA

CDER senior advisor for clinical science Bob Temple retires, and FDA principal deputy commissioner Namandj Bumpus leaves the agency ahead of the new i...

latest-news-card-1
Biologics

Xbrane Refiles Lucentis Biosimilar BLA

Xbrane Biopharma refiles a BLA for its investigational ranibizumab, a biosimilar copy of Genentechs age-related macular degeneration drug Lucentis.

latest-news-card-1
Medical Devices

Alert on AquaFlexFlow Blood Circuits

FDA issues a safety alert on Nuwellis AquaFlexFlow UF 500 Plus extracorporeal blood circuit because the device may trigger a weight mismatch alarm whi...

latest-news-card-1
Human Drugs

Senators Introduce Skinny Label Generic Drug Bill

Four senators introduce bipartisan legislation to protect generic drug manufacturers from innovator drug lawsuits over skinny labeled generics.